PD-1/PD-L1
Les inhibiteurs de PD-1/PD-L1 sont des inhibiteurs de points de contrôle immunitaires qui bloquent l'interaction entre la protéine de mort cellulaire programmée 1 (PD-1) sur les cellules T et son ligand PD-L1 sur les cellules cancéreuses. Cette interaction supprime normalement la réponse immunitaire et permet aux cellules cancéreuses d'échapper à la détection immunitaire. En inhibant PD-1/PD-L1, ces inhibiteurs renforcent la capacité du système immunitaire à reconnaître et à détruire les cellules cancéreuses, induisant l'apoptose et la régression tumorale. Les inhibiteurs de PD-1/PD-L1 sont essentiels dans la recherche en immunothérapie et dans le traitement du cancer. Chez CymitQuimica, nous offrons une gamme d'inhibiteurs de PD-1/PD-L1 de haute qualité pour soutenir vos recherches en immuno-oncologie, apoptose et thérapie contre le cancer.
150 produits trouvés pour "PD-1/PD-L1".
Trier par
Degré de pureté (%)
0
100
|
0
|
50
|
90
|
95
|
100
Human PD-L1 inhibitor II
CAS :Human PD-L1 inhibitor II is a potent PD-L1 inhibitor with anti-cancer activity.Formule :C103H151N25O30Couleur et forme :SolidMasse moléculaire :2219.486Eciskafusp alfa
CAS :Eciskafusp alfa, a cis-targeted IL2v immunocytokine, acts on programmed cell death 1 (PDCD1, commonly known as PD-1), preferentially targeting antigen-specificDegré de pureté :98%Couleur et forme :SolidAnti-Mouse PD-L1 Antibody (10F.9G2)
Anti-Mouse PD-L1 Antibody (10F.9G2) is an IgG-class antibody against mouse PD-L1.Degré de pureté :98.92% - >95.0% (SDS-PAGE); 99.6% (SEC-HPLC)Couleur et forme :Transparent LiquidMasse moléculaire :150 kDaGarivulimab
CAS :Garivulimab (BGB-A333) is a humanized mAb targeting PD-L1 that enhances T-cell anti-tumor activity by blocking the PD-1/PD-L1 pathway.Degré de pureté :95%Couleur et forme :Transparent LiquidTQB-2858
TQB-2858 is a bifunctional fusion protein composed of an anti-PD-L1 monoclonal antibody fused with the extracellular domain of the TGF-β receptor. It exhibits high affinity for PD-L1, TGF-β1, and TGF-β3, and demonstrates a high target occupancy rate for PD-L1. TQB-2858 can be used in research on osteosarcoma and alveolar soft part sarcoma (ASPS).Couleur et forme :Odour LiquidPD-1/PD-L1-IN-49
PD-1/PD-L1-IN-49 (compound 1c) is a potent inhibitor of PD-1/PD-L1 with an IC50 of 77 nM. This compound can activate Jurkat T cells and effectively block the PD-1/PD-L1 immune checkpoint.Formule :C27H32N4O5Couleur et forme :SolidMasse moléculaire :492.567Human membrane-bound PD-L1 polypeptide
CAS :Human membrane-bound PD-L1 polypeptide serves as an antigen for inducing the production of PD-L1 antibodies [1].Formule :C85H140N26O36SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :2134.24Human PD-L1 inhibitor IV
CAS :PD-L1 inhibitor IV, a polypeptide, competitively blocks hPD-1 with a Kd of 1.38 μM, preventing hPD-1/hPD-L1 interaction.Formule :C80H113N25O27Couleur et forme :SolidMasse moléculaire :1856.932PD-L1 inhibitory peptide
CAS :PD-L1inhibitory peptide is an inhibitor peptide that targets the programmed cell death ligand 1 (PD-L1). By binding to PD-L1, it lifts immune suppression and restores the anti-tumor activity of T cells. PD-L1inhibitory peptide holds promise for use in tumor research.Formule :C96H135N21O23SCouleur et forme :SolidMasse moléculaire :1983.29PD-L1/VISTA-IN-2
PD-L1/VISTA-IN-2 (Compound S8) is an orally active dual inhibitor targeting PD-L1 and VISTA, with an IC50 of 1.4 μM for PD-L1 and a KD of 2.1 μM for VISTA. This compound can activate the tumor immune microenvironment, exerting anticancer effects.Formule :C22H22N2O3Couleur et forme :SolidMasse moléculaire :362.42PD-1/PD-L1-IN-51
PD-1/PD-L1-IN-51 (Compound III-4) is an inhibitor of PD-1/PD-L1 (IC50: hPD-L1 at 2.9 nM). It binds directly to PD-L1, blocking the interaction between PD-1 and PD-L1, and enhancing the release of IFN-γ. Additionally, PD-1/PD-L1-IN-51 exhibits antitumor activity.Couleur et forme :Odour SolidTPP-1 TFA
TPP-1 TFA is a high-affinity PD-L1 inhibitor (KD=95nM) that boosts T-cell function to curb tumor growth.Formule :C109H151F3N34O34S2Couleur et forme :SolidMasse moléculaire :2602.69PD-1/PD-L1-IN-50
Compound LG-12, known chemically as PD-1/PD-L1-IN-50, is an inhibitor of PD-1/PD-L1. It enhances the secretion of IFN-γ, promotes the activation of CD8+ T cells, and activates T cell-mediated anti-tumor immunity.Couleur et forme :Odour SolidPD-1/PD-L1-IN-39
PD-1/PD-L1-IN-39 (X 14) is an orally active PD-1/PD-L1 inhibitor with an IC50 value of 15.73 nM. It exhibits strong binding affinity to human and mouse PD-L1, with KD values of 14.62 and 392 nM, respectively. PD-1/PD-L1-IN-39 also demonstrates antitumor activity.Formule :C23H20ClFN2O3Couleur et forme :SolidMasse moléculaire :426.11465PD-1/PD-L1-IN-9
CAS :PD-1/PD-L1-IN-9, with an IC50 of 3.8 nM, is a potent and orally active inhibitor of the PD-1/PD-L1 interaction.Formule :C22H24N2O2Degré de pureté :99.92%Couleur et forme :SolidMasse moléculaire :348.44Ref: TM-T9651
10mgÀ demander25mgÀ demander50mgÀ demander100mgÀ demander500mgÀ demander1mg57,00€2mg85,00€5mg127,00€1mL*10mM (DMSO)140,00€PD-1/PD-L1-IN-48
PD-1/PD-L1-IN-48 (compound HD10) is an effective inhibitor of the PD-1/PD-L1 interaction, exhibiting an IC50 of 3.1 nM. It plays a vital role in cancer research.Couleur et forme :Odour SolidHuman PD-L1 inhibitor I
CAS :Human PD-L1 inhibitor I, a peptide, blocks PD-L1/PD-1 interaction with 3.39 μM affinity.Formule :C110H152N26O32Couleur et forme :SolidMasse moléculaire :2350.576BMSpep-57
CAS :BMSpep-57: Macrocyclic peptide, inhibits PD-1/PD-L1, IC50=7.68 nM, binds PD-L1 (Kd=19 nM/MST, 19.88 nM/SPR), boosts T cell IL-2 in PBMCs.Formule :C89H126N24O19SCouleur et forme :SolidMasse moléculaire :1868.2Iparomlimab
CAS :Iparomlimab serves as a functional therapeutic tool specifically designed to enable the precise detection and neutralization of the PD-1 protein which plays a pivotal role in the induction of peripheral tolerance and tumor immune evasion during strictly monitored laboratory observation periods and molecular investigations to evaluate the pharmacological potential of targeted checkpoint inhibition in specialized preclinical research environments to facilitate the study of cancer immunotherapies.Degré de pureté :95%Couleur et forme :Transparent LiquidPROTAC PD-L1 degrader-1
PROTACPD-L1 degrader-1 is a CRBN-based PD-L1-PROTAC degrader with significant PD-L1 protein degradation capacity. It demonstrates strong PD-L1 degradation activity in 4T1 cells, with a DC50 of 0.609 μM. This compound is applicable to breast cancer research.Couleur et forme :Odour Solid
